Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme
Filed with HKEX · Stock code 1093 · · 3 pages · English
Summary by 6ix AI
The grant aims to incentivize and retain key individuals, aligning their interests with those of shareholders. Following this grant, the number of shares available for future grants under the scheme has been updated.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/voluntary-announcement-grant-of-awarded-shares-pursuant-to-the-2018-share-award-scheme
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China
- Voluntary announcement - SYS6062 (antibody-drug conjugate) obtains clinical trial approval in China
- Voluntary announcement - data from Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer presented as a rapid oral presentation at the 2026 annual global meeting of the international gynecologic cancer society (igcs 2026)
- Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
Later from CSPC Pharmaceutical
- Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme
- Voluntary announcement - phase i clinical trial of SYH2083 eye drops for the treatment of dry eye disease officially initiated in china
- Voluntary announcement - phase ii clinical trial of SYH2066 for the treatment of respiratory syncytial virus infection officially initiated in china
- Voluntary announcement - phase iii clinical trial of SYS6043 for the first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer officially initiated in china
- Voluntary announcement - batoclimab injection (subcutaneous injection) obtains drug registration certificate from the nmpa
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical